Sept. 7, 2018 Dear Friends: The new PFS Foundation website is finally here, and we couldn’t be more enthusiastic, because it promises to speed along numerous global-awareness and patient-support efforts. You’ll note that the homepage features an info-graphic called “PFS by the Numbers” that functions as a running tab of data in six categories: Adverse […]
July 28, 2018 Dear Friends: Canada has taken an important first step toward keeping its citizens apprised of finasteride’s many potentially serious and persistent side effects. In the June edition of its Health Product InfoWatch, Health Canada (Canada’s version of the US Food and Drug Administration) reported that “New information regarding the risk of muscle-related […]
SOMERSET, N.J., July 1, 2013 – The Post-Finasteride Syndrome Foundation today announced the funding of a major clinical study on post-finasteride syndrome (PFS) at Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School. Titled “A Preliminary, Hypothesis-Generating Investigation of the Post-Finasteride Syndrome: Description of the Phenotype, and Elucidation of the Hormonal, Genetic […]
SOMERSET, N.J., March 25, 2013 – The roundtable discussion at the 7th international steroids and nervous system meeting in Orbassano (TO), Italy, February 16th – 20th 2013, included scientific presentations and discussions amongst multiple medical researchers regarding the Post-Finasteride Syndrome. This event was a great opportunity for the PFS Foundation to increase awareness of PFS […]
SOMERSET, N.J., March 18, 2013 – The Post-Finasteride Syndrome Foundation today announced that it has been granted 501(c)(3) status by the Internal Revenue Service. “Nonprofit status will allow us to put more dollars to work pursuing our core goal, which is funding research on the characterization, underlying biologic mechanisms and treatments of PFS,” added Dr. […]
July 6, 2018 Dear Friends: Apparently heeding an appeal by Germany’s largest weekly newspaper, the Federal Institute for Drugs and Medical Devices (BfArM) has dispatched a so-called Red Hand Letter to doctors and pharmacists nationwide, informing them of severe and persistent adverse drug reactions (ADRs) to finasteride. Five months ago, we told you that Die […]
May 20, 2018 Dear Friends: Yet another European nation has taken to the airwaves with PFS awareness. This time it’s Switzerland. The network is Swiss Radio and Television (SRF). And the program is Puls. On May 7, the weekly health-news magazine debuted a special report titled Do Anti-Baldness Remedies Make You Impotent? (English-subtitled version here.) […]
March 12, 2018 Dear Friends: PFS is a growing concern in Germany, too. Ditto Albania. In December, we told you that the French National Agency for Drug Safety (ANSM) launched a public-awareness campaign warning against reported mood changes in Propecia patients, “particularly depression, and suicidal ideation.” Now we’re encouraged to report that Die Zeit, Germany’s […]
May 26, 2017 Dear Friends: The UK’s equivalent of the US Food and Drug Administration, the Medicines and Healthcare Products Regulatory Agency (MHRA), has issued a drug safety update on finasteride. The May 24 document, titled Finasteride: rare reports of depression and suicidal thoughts, states: Some men have reported episodes of depressive illness in association with […]
SOMERSET, N.J., March 9, 2017 – More than one percent of young men who took finasteride for 206 days or longer developed persistent erectile dysfunction (PED) that lasted an average of 4.2 years after drug discontinuation, according to a new study published today in PeerJ. In all, researchers examined the electronic medical records (EMR) of […]